AdipexThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5

228 records returned

2010 ASN AbstractsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: VBD can enlarge to significant dimensions, producing compressive symptoms in the brainstem, as well as thrombosis and ischemic strokes. SACE of the dolichoectasia can be effective for the vessel reconstruction, to prevent progression of the dilatation, and other potential clinical events. 3. Three Case Reports of Multiple Carotid and/or Vertebral Artery Dissections in Female Mei Lu, Heather Gornik, Esteban Cheng Ching, Vikram Kashyap, Rishi Gupta Cleveland Clinic Foundation, Cleveland, OH 44195, United States Introduction: Multiple carotid and/or vertebral artery dissections are rare. However, patients with mul...
Source: Journal of Neuroimaging - November 11, 2009 Category: Radiology Source Type: journals

The Roles of Dopamine Transport Inhibition and Dopamine Release Facilitation in Wake Enhancement and Rebound Hypersomnolence Induced by Dopaminergic AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: All DA releasing agents tested, and some DAT-inhibiting agents, produced RHS at equal wake-promoting doses. Thus amphetamine-like DA release appears sufficient for inducing RHS, but additional properties (pharmacologic and/or pharmacokinetic) evidently underlie RHS of other DAT inhibitors. Enhancing wake while mitigating RHS can be achieved by combining DAT-inhibiting and DA-releasing agents. Keywords: Sleep/wake, dopamine transporter, amphetamine, hypersomnolence, pharmacokinetic, rat (Source: Sleep)
Source: Sleep - October 31, 2009 Category: Sleep Medicine Source Type: journals

PHENTERMINE HYDROCHLORIDEtablet [Physicians Total Care, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Oct 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 30, 2009 Category: Drugs & Pharmacology Source Type: organizations

Phentermine: Can prescription medication help weight loss?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Phentermine — Combine phentermine with diet and exercise to boost weight loss. Sponsored by:Chemotherapy.com - http://www.chemotherapy.com (Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - October 24, 2009 Category: Consumer Health News Source Type: news

Phentermine: Can prescription medication help weight loss?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Phentermine — Combine phentermine with diet and exercise to boost weight loss. Sponsored by:Chemotherapy.com - http://www.chemotherapy.com (Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - October 23, 2009 Category: Consumer Health News Source Type: news

PHENTERMINE HYDROCHLORIDEtablet [TEVA Pharmaceuticals USA Inc]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Oct 20, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - October 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-MorbiditiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
September 9, 2009 (VIVUS) - VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes. ...
Source: Diabetes News from dLife.com - October 8, 2009 Category: Consumer Health News Authors: dlife Source Type: info

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study assessed the potential pharmacokinetic interaction and safety/tolerability of taranabant and phentermine coadministration. This was a randomized, double-blind, 3-panel, fixed-sequence study in healthy participants. Panels A, B, and C evaluated the safety/tolerability of phentermine 15 mg coadministered with taranabant 0.5, 1, and 2 mg for 7 days (panel A) and 28 days (panels B and C). In panels A and C, phentermine 15 mg was administered both with (7 days, panel A; 28 days, panel C) and without (7 days) taranabant 0.5 mg or 2 mg to evaluate pharmacokinetics. The primary endpoint was phentermine AUC(0-24 h) in pa...
Source: The Journal of Clinical Pharmacology - September 30, 2009 Category: Drugs & Pharmacology Authors: Addy C, Jumes P, Rosko K, Li S, Li H, Maes A, Johnson-Levonas AO, Chodakewitz J, Stoch SA, Wagner JA Tags: J Clin Pharmacol Source Type: journals

Phentermine cardiovascular safetyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A recent case report published in the American Journal of Emergency Medicine described a 48-year-old woman with no significant medical history who developed a myocardial infarction and subsequent ventricular tachycardia/fibrillation. This patient also happened to be taking phentermine, and the authors therefore conclude “that this agent, which is a chemical analogue of the potent amphetamine class of noradrenergic stimulants, may have the ability to promote potentially fatal cardiac outcomes.” We believe that the authors have left the reader with an unbalanced and exaggerated impression that phentermine is a dangerous ...
Source: The American Journal of Emergency Medicine - September 24, 2009 Category: Emergency Medicine Authors: Richard B. Rothman, Ed J. Hendricks Tags: Correspondence Source Type: journals

Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valvesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, we have identified a novel mechanism whereby MAO-A can contribute to increased oxidative stress in human heart valves and pulmonary artery exposed to serotonin and dopamine. (Source: AJP: Heart and Circulatory Physiology)
Source: AJP: Heart and Circulatory Physiology - September 23, 2009 Category: Cardiology Authors: Pena-Silva, R. A., Miller, J. D., Chu, Y., Heistad, D. D. Tags: ARTICLES Source Type: journals

PHENTERMINE HYDROCHLORIDEtablet [TEVA Pharmaceuticals USA Inc]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Sep 22, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 22, 2009 Category: Drugs & Pharmacology Source Type: organizations

New Obesity Drug Qnexa Showed Positive Results In Late Stage Trials Test Says CompanyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
According to Vivus Inc, their experimental drug Qnexa for treating obesity showed positive results in late stage trials, where patients who took the new diet pill, a combination of phentermine (a stimulant) and topiramate (an anticonvulsant), shed an average of nearly 15 per cent of their body (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 10, 2009 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Two Old Drugs Add Up to One New Diet PillEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patients taking a novel diet drug that combines the stimulant phentermine with the anticonvulsant topiramate lost an average of 37 pounds over a year with significant improvement in a number of cardiovascular risk factors, according to an announcement from Vivus, the developer of the drug. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - September 9, 2009 Category: Pediatrics Source Type: news

Positive results from phase III studies of QnexaT (phentermine and topiramate) as weight loss treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: BioSpace Area: News VIVUS Inc. has announced positive results from two phase III 56-week studies (EQUIP and CONQUER) of its investigational weight loss treatment QnexaT, a once daily oral, controlled-release formulation of low dose phentermine and topiramate. The phase III programme evaluated three doses of Qnexa (milligrams phentermine and controlled release topiramate, respectively): Qnexa 15/92 (full dose), Qnexa 7.5/46 (mid dose) and Qnexa 3.75/23 (low dose). EQUIP was a randomised, double-blind, placebo-controlled, 3-arm, prospective trial in 1267 morbidly obese patients (1050 females an...
Source: NeLM - News - September 9, 2009 Category: Drugs & Pharmacology Source Type: organizations

Serotonin Produces Monoamine Oxidase-dependent Oxidative Stress in Human Heart Valves.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, we have identified a novel mechanism whereby MAO-A can contribute to increased oxidative stress in human heart valves and pulmonary artery exposed to serotonin and dopamine. Key words: 5-HT, reactive oxygen species, carcinoid syndrome, superoxide. PMID: 19666839 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Heart and Circulatory Physiology)
Source: American Journal of Physiology. Heart and Circulatory Physiology - August 6, 2009 Category: Physiology Authors: Pena-Silva RA, Miller JD, Chu Y, Heistad DD Tags: Am J Physiol Heart Circ Physiol Source Type: journals

ADA 2009: New Weight-Loss Drug Stops Progression Toward Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Phentermine and controlled-release topiramate change the hemoglobin A1c trajectory; the combination arrests progression to type 2 diabetes in obese nondiabetic individuals. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2009 Category: Consumer Health News Tags: Diabetes & Endocrinology Source Type: news

The sale of weight-loss supplements on the Internet: A lurking health care crisis waiting to strikeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Worldwide, obesity has assumed epidemic proportions. Between 2003 and 2004, 32.2% of adults in the United States were classified as obese (body mass index ≥30 kg/m2). Many obese individuals have difficulty trying to lose weight using the conventional methods of diet and exercise, and, under mounting medical and societal pressures, many are compelled to seek an “easy fix” through pharmaceutical agents. The Internet has become a popular venue for the sale and purchase of such supplements, raising fears that lack of regulation may expose consumers to life-threatening risks. The use of pharmaceutical agents to help lose ...
Source: Heart Rhythm - April 22, 2009 Category: Cardiology Authors: Munther K. Homoud Tags: Editorial Commentary Source Type: journals

How Physician Obesity Specialists Use Drugs to Treat Obesity.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Specialist physicians may have prescribing habits that are different from nonspecialist physicians. Little is known about the prescribing habits of physicians specializing in the treatment of obesity. An anonymous survey was given to the physician members of the American Society of Bariatric Physicians (ASBP). There was a 35% response rate (266 physicians) to the questionnaire that was represented nationally. Almost all prescribed medications and all of them recommended phentermine. The average maximal dose of phentermine was above that approved in the package insert, and these physicians disagreed with the National In...
Source: Obesity - March 19, 2009 Category: Eating Disorders and Weight Management Authors: Hendricks EJ, Rothman RB, Greenway FL Tags: Obesity (Silver Spring) Source Type: journals

Response to IJC-D-08-03075 entitled "Phentermine Cardiovascular Safety"Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19303652 [PubMed - as supplied by publisher] (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - March 19, 2009 Category: Cardiology Authors: Yosefy C Tags: Int J Cardiol Source Type: journals

Ionamin 30mgEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ionamin (phentermine) is a diet pill. (Source: About.com Alcoholism)
Source: About.com Alcoholism - March 7, 2009 Category: Addiction Authors: alcoholism.guide at about.com Tags: health Source Type: consumer

[Letters to the Editor] Cross-Reactivity of Phentermine with an Immunoassay Designed to Detect Amphetamine in a Meconium SpecimenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Clinical Chemistry)
Source: Clinical Chemistry - February 25, 2009 Category: Chemistry Authors: Marin, S. J., Moore, C., McMillin, G. A. Tags: Letters to the Editor Source Type: journals

PHENTERMINE (Phentermine Hydrochloride) Tablet [Actavis Elizabeth LLC]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Feb 20, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

Obesity: pathophysiology and clinical management.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Obesity is an increasingly serious socioeconomic and clinical problem. Between (1/4)-(1/3) of population in the developed countries can be classified as obese. Four major etiological factors for development of obesity are genetic determinants, environmental factors, food intake and exercise. Obesity increases the risk of the development of various pathologic conditions including: insulin-resistant diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, endocrine problems, and certain forms of cancer. Thus, obesity is a negative determinant for longevity. In this review we provide broad overview of...
Source: Current Medicinal Chemistry - February 11, 2009 Category: Chemistry Authors: Gurevich-Panigrahi T, Panigrahi S, Wiechec E, Los M Tags: Curr Med Chem Source Type: journals

Phentermine cardiovascular safety In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A letter to the editor "Cusp tear in bicuspid valve possibly caused by phentermine" published in volume 106 (2006) stated "Phentermine is known to cause valvular disease with prolonged use." There is no evidence that phentermine causes valvulopathy. Phentermine is the most widely used anti-obesity drug. In view of the serious cardiovascular risks associated with obesity, it is important to clarify that phentermine is a safe and effective anti-obesity medication. PMID: 19189876 [PubMed - as supplied by publisher] (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - February 1, 2009 Category: Cardiology Authors: Rothman RB, Hendricks EJ Tags: Int J Cardiol Source Type: journals

Oxethazaine as the source of mephentermine and phentermine in athlete's urine.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study applied LC-MS-MS to analyze the excretions of three volunteers who ingested oxethazaine and presented positive results for mephentermine and/or phentermine. Thus, oxethazaine is the source of mephentermine and phentermine. Moreover, the results showed that 48 brands of gastric medicines containing oxethazaine were legally imported or locally manufactured in Taiwan, information which could be useful for limiting the misuse of oxethazaine by athletes. The data suggested that the sports associations should warn athletes about the risks of taking oxethazaine. PMID: 19157735 [PubMed - as supplied by publisher] (S...
Source: Forensic Science International - January 19, 2009 Category: Forensic Medicine Authors: Hsu MC, Lin SF, Kuan CP, Chu WL, Chan KH, Chang-Chien GP Tags: Forensic Sci Int Source Type: journals

Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Recent voluntary withdrawal of the ergoline-derivative Alzheimers' drug Pergolide (Permax) resulting from demonstrated risk of cardiac valve injury illustrates the increased importance of valve injury in pharmaceutical toxicology. Following the 2001 landmark discovery of cardiac valve injury associated with the widely prescribed anti-obesity drug combination fenfluramine-phentermine, and subsequent withdrawal, the need to understand and assess cardiac valve biology and pathology both preclinically and clinically has been accentuated. Unique aspects of the developmental biology, anatomy, and physiology of cardiac valves...
Source: Toxicologic Pathology - September 5, 2008 Category: Pathology Authors: Donnelly KB Tags: Toxicol Pathol Source Type: journals

Phentermine: Heart arrest and myocardial infarction: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - July 21, 2008 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Phentermine: Heart arrest and myocardial infarction: case report.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Page: 26 (Source: Reactions Weekly)
Source: Reactions Weekly - July 19, 2008 Category: Drugs & Pharmacology Tags: HTML Source Type: journals

Cardiac arrest in the setting of diet pill consumption.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The obesity epidemic currently plaguing the United States has spurred the development of a vast number of drugs to assist in the battle against obesity and its associated complications. The need to loose weight often causes patients to loose sight of or even ignore the serious side effects of some of the most widely used weight-loss medications. Here we present the case of ventricular tachycardia/fibrillation arrest in an otherwise healthy 48-year-old woman who was taking no medications other than phentermine, a common appetite suppressant that functions as a central nervous system stimulant through activation of the n...
Source: The American Journal of Emergency Medicine - July 1, 2008 Category: Emergency Medicine Authors: Makaryus JN, Makaryus AN Tags: Am J Emerg Med Source Type: journals

Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats International Journal of Obesity advance online publication, June 17, 2008. doi:10.1038/ijo.2008.91 Authors: J D Roth, J L Trevaskis, J Wilson, C Lei, J Athanacio, C Mack, N C Kesty, T Coffey, C Weyer & D G Parkes (Source: International Journal of Obesity)
Source: International Journal of Obesity - June 17, 2008 Category: Eating Disorders and Weight Management Authors: J D RothJ L TrevaskisJ WilsonC LeiJ AthanacioC MackN C KestyT CoffeyC WeyerD G Parkes Source Type: journals

Phentermine Hydrochloride(Phentermine Hydrochloride) Capsule Phentermine Hydrochloride(Phentermine Hydrochloride) Tablet [Actavis Totowa LLC]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: May 22, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 22, 2008 Category: Drugs & Pharmacology Source Type: organizations

Review: Non-surgical management of obesity in adultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this review in the New England Journal of Medicine, the authors present a case vignette followed by a discussion of the following topics relating to the non-surgical management of obesity in adults: • Clinical problem • Evaluation • Lifestyle approaches (diet, physical activity, behavioural modification) • Pharmacological therapy (phentermine, diethylpropion, sibutramine, orlistat, rimonabant) • Maintenance of weight reduction • Areas of uncertainty • Guidelines (Source: NeLM Headline News)
Source: NeLM Headline News - May 1, 2008 Category: Drugs & Pharmacology Tags: 4.5 Drugs used in the treatment of obesity, Obesity, Drug reviews Source Type: organizations

Fen-Phen Judge Awards Attorneys $414 Million In Common Benefit FeesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - The judge supervising the American Home Products (AHP) National Settlement has made a final distribution of approximately $414 million in legal fees to the law firms that prosecuted the 10-year litigation and administered the resulting national settlement (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.). Full story on lexis.com (Source: LexisNexis® Mealey's™ Emerging Drugs & Devices Legal News)
Source: LexisNexis® Mealey's™ Emerging Drugs & Devices Legal News - April 18, 2008 Category: Medical Law Source Type: info

Phentermine Hydrochloride(Phentermine Hydrochloride) Tablet [Qualitest Pharmaceuticals]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Mar 19, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - March 19, 2008 Category: Drugs & Pharmacology Source Type: organizations

Phentermine(Phentermine Hydrochloride) Tablet [Actavis Elizabeth LLC]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Feb 15, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2008 Category: Drugs & Pharmacology Source Type: organizations

MIP Technologies and Supelco Launch a New Selective SPE Product for the Extraction of Amphetamine and Related DrugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SupelMIP SPE-Amphetamines improves detection limits up to one hundred times compared with existing SPE phases on the market MIP Technologies AB and Supelco, a division of Sigma-Aldrich Corporation, announced today the launch of a new SupelMIP product for the selective extraction of amphetamine and related drugs. A simple, fast, selective and highly sensitive SPE product has been developed for trace-level determinations in forensic, toxicological and pharmaceutical testing. The SPE phase has been evaluated for amphetamine, methamphetamine, phentermine, MDA, MDMA and MDEA. Recoveries are high and the extracts show mini...
Source: Pharmaceutical Technology - January 30, 2008 Category: Pharmaceuticals Source Type: info

Longitudinal Effects of Fenfluramine--Phentermine UseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Angiology)
Source: Angiology - January 23, 2008 Category: Cardiology Authors: Bhattacharyya, S., Constantin, C., Davar, J., Mikhailidis, D. Tags: Article Source Type: journals

Judge Says Dispute Over Cause Of PPH Is An Issue Of FactEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - Although a diet drug user must offer a reasonable scientific basis to assert a claim of primary pulmonary hypertension (PPH), it is not the role of the diet drug multidistrict litigation court to make a finding of fact on the relative credibility of the plaintiff's and Wyeth's experts, the MDL judge held Nov. 30 (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; Kathryn A. Decker, et al. v. Indevus Pharmaceuticals Inc., et al., No. 06-4461, Mass. Super.; 2007 U.S. Dist....
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Special Master Recommends PPH Plaintiff Not Be Allowed To Pursue Claims At TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - The diet drug special master on Dec. 31 recommended against allowing a plaintiff to assert primary pulmonary hypertension (PPH) at trial in the Philadelphia Court of Common Pleas, saying it is a settled claim because the plaintiff failed to rule out primary cardiac disease as a cause of her elevated pulmonary arterial pressure (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa., Nancy Cochran v. Wyeth, et al., No. 000275, Pa. Comm. Pls., Phila. Co.; See December 2007, Pag...
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Court Redefines Special Master's ResponsibilitiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - Now that Special Master Gregory P. Miller has gone into the private practice of law with Philadelphia's Drinker, Biddle & Reath, the judge supervising the diet drug multidistrict litigation has issued an order resolving potential conflicts between the special master's new and continuing responsibilities (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 88962; See September 2007, Page 16). Full story on lexis.com (Source: LexisNexis® Meal...
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Improper Opt-Out Suit Ruled A Bar To Woman's Settlement Benefits PetitionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - The judge supervising the diet drug multidistrict litigation has ruled that a claimant's failure to withdraw an improper opt-out suit against Wyeth was dismissed with prejudice, precluding her from later seeking settlement benefits (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; 2007 U.S. Dist. LEXIS 91175). Full story on lexis.com (Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News)
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Judge Rules Claimants Properly Sought Entry Into Show-Cause ProceedingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - The judge supervising the American Home Products National Settlement has ruled that two claimants may proceed to a show-cause proceeding to argue for payment of claims approved nearly four years ago but later withdrawn (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.). Full story on lexis.com (Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News)
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Class Counsel Says Settlement Echo Criteria Were Chosen As GenerousEmail this article to a colleague. Save this article to My Clippings. discuss this article 1 CommentDiscuss or comment on this article.
PHILADELPHIA - Class counsel has responded to three unsuccessful pro se claimants, saying that the echocardiogram criteria in the American Home Products National Settlement Agreement were chosen as the most likely to demonstrate compensable injury levels for most claimants and that other methodologies would not have yielded a better result for the three objectors (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See December 2007, Page 11). Full story on lexis.com (Source: LexisNexi...
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Law Firm Attacks New Program Notice As Insufficient To ClassEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - A Missouri law firm has objected to a jointly proposed procedure that would yield reduced benefits but faster resolution of nearly 90 percent of disputed Matrix claims, saying Court Approved Procedure (CAP) 15 does not provide class members with sufficient notice of how their claims would be handled (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See December 2007, Page 4). Full story on lexis.com (Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News)
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Class Counsel Says Objector Slanders Them, Demonstrates ContemptEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - Class counsel has turned up the heat under a Texas attorney who opposes paying a common benefit fee in the diet drug multidistrict litigation as well as the size of the request for more than $400 million in common benefit fees, saying he has added to his alleged sins slander, contempt and violations of the Federal Rules of Civil Procedure (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.; See November 2007, Page 8). Full story on lexis.com (Source: LexisNexis® Mea...
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - January 18, 2008 Category: Medical Law Source Type: info

Lannett Receives FDA Approval For PhentermineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lannett Company, Inc. (Amex:LCI) announced it has received approval from the U.S. Food and Drug Administration (FDA) for the company's supplemental Abbreviated New Drug Application (ANDA) of Phentermine Hydrochloride Capsules 30 mg. The company expects to commence marketing this product immediately. Phentermine Hydrochloride (HCl) is indicated for the short-term management of obesity. [click link for full article] (Source: Obesity / Weight Loss / Fitness News From Medical News Today)
Source: Obesity / Weight Loss / Fitness News From Medical News Today - December 14, 2007 Category: Eating Disorders and Weight Management Source Type: news

Different dosage of Lannett obesity drug OK'dEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Food and Drug Administration approved Lannett Co. Inc.'s application to market a generic 30-milligram version of a medication for the short-term management of obesity called phentermine hydrochloride. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 12, 2007 Category: Pharmaceuticals Source Type: journals

Parties Propose Procedure That Would Resolve Most Claims Held Up By TrustEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - The parties in the American Home Products National Settlement have proposed another procedure that would yield reduced benefits but faster resolution of nearly 90 percent of claims flagged by the Settlement Trust for alleged intentional manipulation of their supporting echocardiograms (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.). Full story on lexis.com (Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News)
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - December 8, 2007 Category: Medical Law Source Type: info

Judge Says Claimant Should Not Pay For Trust's Echo FailureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA - A claimant whose injury is worth $462,103 should not be penalized by the American Home Products Settlement Trust's failure to provide an adequate echocardiogram, nor should the trust be allowed to use that substandard study to assert a reduction factor in the claimant's compensation, the judge supervising the AHP National Settlement has ruled (In Re: Diet Drugs [Phentermine/Fenfluramine/Dexfenfluramine] Products Liability Litigation, MDL Docket No. 1203, Sheila Brown, et al. v. American Home Products Corp., No. 99-20593, E.D. Pa.). Full story on lexis.com (Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News)
Source: LexisNexis® Mealey's™ Fen-Phen/Redux Legal News - December 8, 2007 Category: Medical Law Source Type: info